全文获取类型
收费全文 | 90281篇 |
免费 | 6172篇 |
国内免费 | 639篇 |
专业分类
耳鼻咽喉 | 1008篇 |
儿科学 | 3133篇 |
妇产科学 | 1927篇 |
基础医学 | 12191篇 |
口腔科学 | 1595篇 |
临床医学 | 8169篇 |
内科学 | 19989篇 |
皮肤病学 | 2291篇 |
神经病学 | 8952篇 |
特种医学 | 2333篇 |
外国民族医学 | 2篇 |
外科学 | 10040篇 |
综合类 | 1638篇 |
一般理论 | 74篇 |
预防医学 | 9214篇 |
眼科学 | 1920篇 |
药学 | 5953篇 |
6篇 | |
中国医学 | 573篇 |
肿瘤学 | 6084篇 |
出版年
2023年 | 918篇 |
2022年 | 729篇 |
2021年 | 3165篇 |
2020年 | 1982篇 |
2019年 | 3080篇 |
2018年 | 3987篇 |
2017年 | 2540篇 |
2016年 | 2557篇 |
2015年 | 2696篇 |
2014年 | 3317篇 |
2013年 | 4607篇 |
2012年 | 7498篇 |
2011年 | 7836篇 |
2010年 | 3968篇 |
2009年 | 3037篇 |
2008年 | 5769篇 |
2007年 | 5796篇 |
2006年 | 5404篇 |
2005年 | 5285篇 |
2004年 | 4757篇 |
2003年 | 4429篇 |
2002年 | 3900篇 |
2001年 | 1786篇 |
2000年 | 2105篇 |
1999年 | 1343篇 |
1998年 | 584篇 |
1997年 | 419篇 |
1996年 | 363篇 |
1995年 | 374篇 |
1994年 | 254篇 |
1993年 | 253篇 |
1992年 | 269篇 |
1991年 | 232篇 |
1990年 | 201篇 |
1989年 | 205篇 |
1988年 | 181篇 |
1987年 | 147篇 |
1986年 | 130篇 |
1985年 | 126篇 |
1984年 | 127篇 |
1983年 | 101篇 |
1982年 | 76篇 |
1981年 | 72篇 |
1980年 | 66篇 |
1979年 | 43篇 |
1978年 | 41篇 |
1977年 | 47篇 |
1976年 | 30篇 |
1975年 | 31篇 |
1973年 | 30篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
肝细胞癌(HCC)是最常见的恶性肿瘤之一。尽管在早期诊断和个体化治疗方面取得了进展,但经根治性切除等治疗后,HCC患者的临床预后仍不佳,复发率高。因此,在HCC患者中识别准确可靠的预后标志物是必要的。作为一种新的免疫营养生物标志物,控制营养状态(CONUT)评分已被报道用于预测癌症患者的预后。本文将对术前CONUT评分与HCC肝切除术后预后的研究进展进行综述。 相似文献
2.
3.
4.
Improving hyperpolarized 129Xe ADC mapping in pediatric and adult lungs with uncertainty propagation
5.
Bradshaw Paige Garber Keegan Shaun Foertsch Madeline Yang George L. Ngwenya Laura B. Srinivasan Vasisht 《Journal of thrombosis and thrombolysis》2022,54(2):295-300
Journal of Thrombosis and Thrombolysis - The ongoing controversy regarding optimal reversal agent for factor Xa-inhibitors is mainly due to lack of comparative data of andexanet alfa (AA) to... 相似文献
6.
Yang Yang Shu Jing Mu Jing He Qiang Chen Fang Hu Yan Zhen Xiaofang 《Clinical rheumatology》2022,41(12):3783-3790
Clinical Rheumatology - To analyze and summarize the clinical features, diagnosis, and treatment of children with Henoch-Schönlein purpura (HSP) complicated by overt gastrointestinal bleeding... 相似文献
7.
Laura A. Huppert MD Ozge Gumusay MD Dame Idossa MD Hope S. Rugo MD 《CA: a cancer journal for clinicians》2023,73(5):480-515
Hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative breast cancer is defined by the presence of the estrogen receptor and/or the progesterone receptor and the absence of HER2 gene amplification. HR-positive/HER2-negative breast cancer accounts for 65%–70% of all breast cancers, and incidence increases with increasing age. Treatment varies by stage, and endocrine therapy is the mainstay of treatment in both early stage and late-stage disease. Combinations with cyclin-dependent kinase 4/6 inhibitors have reduced distant recurrence in the early stage setting and improved overall survival in the metastatic setting. Chemotherapy is used based on stage and tumor biology in the early stage setting and after endocrine resistance for advanced disease. New therapies, including novel endocrine agents and antibody-drug conjugates, are now changing the treatment landscape. With the availability of new treatment options, it is important to define the optimal sequence of treatment to maximize clinical benefit while minimizing toxicity. In this review, the authors first discuss the pathologic and molecular features of HR-positive/HER2-negative breast cancer and mechanisms of endocrine resistance. Then, they discuss current and emerging therapies for both early stage and metastatic HR-positive/HER2-negative breast cancer, including treatment algorithms based on current data. 相似文献
8.
9.
10.
Davide Fiore Bavaro Flavia Balena Luigi Ronga Fabio Signorile Federica Romanelli Stefania Stolfa Eleonora Sparapano Carmela De Carlo Adriana Mosca Laura Monno Gioacchino Angarano Annalisa Saracino 《Journal de Mycologie Médicale》2022,32(1):101206
An increased number of patients is at risk of Candida spp. bloodstream infection (CBSI) in modern medicine. Moreover, the rising of antifungal resistance (AR) was recently reported. All consecutive CBSI occurred in our Hospital (consisting of 1,370 beds) between 2015 and 2018, were reviewed. For each case, Candida species, AR pattern, ward involved and demographic data of patients were recorded. Overall, 304 episodes of CBSI occurred, with a median (q1:first-,q3:third quartile) of 77 (71-82) CBSI/year. Over the years, a significant increase of CBSI due to C. albicans compared to non-albicans strains was recorded in medical wards (from 65% to 71%, p=0.030), while this ratio remained stable in others. An increase of resistant strains to multiple antifungals such as C. guillermondii was noticed in recent years (from 0% to 9.8%, p=0.008). Additionally, from 2015 to 2018 an increase in fluconazole-resistance was recorded in our Hospital (from 7.4% to 17.4%, p=0.025) and a slight increase in voriconazole-resistance (from 0% to 7% in 2018, p=0.161) was observed, while resistance to echinocandin and amphotericin B remained firmly below 2%.This study suggests a rapid spread of antifungal resistance in our Hospital; therefore, an appropriate antifungal stewardship programs is urgently warranted. 相似文献